Connor, Clark & Lunn Investment Management (CC&L)
TGTX icon

Connor, Clark & Lunn Investment Management (CC&L)’s TG Therapeutics TGTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-144,648
Closed -$2.57M – 1638
2024
Q2 		$2.57M Sell
144,648
-87,699
-38% -$1.4M 0.01% 588
2024
Q1 		$3.53M Sell
232,347
-113,857
-33% -$1.81M 0.02% 508
2023
Q4 		$5.91M Buy
+346,204
New +$4.02M 0.03% 377
2023
Q3 		– Sell
-327,606
Closed -$8.14M – 1538
2023
Q2 		$8.14M Buy
+327,606
New +$8.46M 0.04% 296
2021
Q3 		– Sell
-18,815
Closed -$730K – 1214
2021
Q2 		$730K Buy
+18,815
New +$739K ﹤0.01% 718
2021
Q1 		– Sell
-24,516
Closed -$1.27M – 1091
2020
Q4 		$1.27M Buy
+24,516
New +$828K 0.01% 592
2020
Q2 		– Sell
-40,103
Closed -$395K – 1167
2020
Q1 		$395K Buy
+40,103
New +$507K ﹤0.01% 749

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TGTX Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 144,648 shares — an estimated $2.57M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TGTX in Q1 2020 and held it in 7 quarters. The position peaked at $8.14M in Q2 2023. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 144,648 TG Therapeutics shares in Q3 2024, an estimated $2.57M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TG Therapeutics in Q1 2020 and held it in 7 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s TG Therapeutics position peaked at $8.14M in Q2 2023.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.